Metastatic Castration-Resistant Prostate Cancer Market Size (7MM) Reached ~USD 8,000 Million in 2025 and is Expected to Grow Through 2036

The Metastatic Castration-Resistant Prostate Cancer (mCRPC) market in the 7 Major Markets (7MM) was valued at approximately USD 8,000 million in 2025 and is projected to show positive growth through 2036, driven by the rising prevalence of prostate cancer in emerging markets amid changing lifestyles, aging populations, and improved access to healthcare. DelveInsight's comprehensive market research provides critical insights into these market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the mCRPC landscape.

By analyzing historical data, current market dynamics, and future projections, DelveInsight equips pharmaceutical companies, investors, and healthcare professionals with actionable intelligence to make informed strategic decisions, identify investment opportunities, optimize product positioning, and plan research and development initiatives effectively.

The mCRPC market continues to be shaped by a diverse and expanding pool of therapeutic classes, including PARP inhibitors, androgen receptor inhibitors, CYP17 inhibitors, microtubule inhibitors, and ionizing radiation emitters. Recent approvals such as AKEEGA (niraparib and abiraterone acetate) and the combination of TALZENNA (talazoparib) with XTANDI (enzalutamide) in 2023 have expanded the treatment armamentarium, while Novartis' radioligand therapy PLUVICTO, approved in 2022, has generated unexpected revenue from the third-line mCRPC setting. As per DelveInsight's assessment, by 2036, PLUVICTO is expected to generate the highest mCRPC revenue in the US, while XTANDI is expected to hold the highest mCRPC drug market share across the EU4 and the UK.

In the 7MM, the United States held the highest mCRPC market share in 2025, contributing approximately 64% of the total metastatic castration-resistant prostate cancer therapeutic market. Based on DelveInsight's 2025 assessment, the 7MM recorded approximately 7.7 million prevalent cases of prostate cancer, with around 43% of all metastatic prostate cancer cases attributed to mCRPC specifically. In the US, roughly 56% of total prostate cancer cases were localized/locally advanced (Stage I–III), approximately 33% were biochemical recurrence/progressive cases, and about 11% were metastatic. Prostate cancer is most frequently diagnosed among men aged 65–74 years, with a median age at diagnosis of 66 years.

DelveInsight's report, "Metastatic Castration-Resistant Prostate Cancer Market Insights, Epidemiology, and Market Forecast – 2036," delivers an in-depth understanding of mCRPC, its historical and forecasted epidemiology, and mCRPC therapeutics market trends across the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.

To know in detail about the mCRPC market outlook, drug uptake, treatment scenario, and epidemiology trends, Click here: Metastatic Castration-Resistant Prostate Cancer Market Forecast

Some of the Key Facts of the mCRPC Market Report:

• Key mCRPC Companies: Curium, Bristol-Myers Squibb, Merck and Orion, Pfizer, Merus, Zenith Epigenetics, MacroGenics, Laekna Therapeutics, Ipsen, AstraZeneca, Telix International, ESSA Pharma, Arvinas and Novartis, Lantheus, Eli Lilly/POINT Biopharma, Xencor, Promontory Therapeutics, and others.
• Key mCRPC Therapies: Mevrometostat (PF-06821497), TAVT-45, 177Lu-PSMA-I&T, Opevesostat (MK-5684; ODM-208), ERLEADA (apalutamide), CABOMETYX (cabozantinib), TRUQAP (capivasertib), Masitinib, 177Lu-PNT2002, 177Lu-DOTA-rosopatamab (TLX591), Fuzuloparib, KPG-121, FPI-2265, Zenocutuzumab, BMS-986218, SX-682, PT-112, Vudalimab (XmAb-20717), OPDIVO (nivolumab), Pamufetinib (TAS-115), MVI-816 (pTVG-HP), Vobramitamab Duocarmazine (MGC018), and others.
• The mCRPC market is expected to grow substantially, propelled by extensive market penetration of approved therapies through label expansions and the entry of new emerging therapies across multiple treatment lines.

Metastatic Castration-Resistant Prostate Cancer Overview

Prostate cancer is a malignancy that occurs in the prostate gland, usually growing slowly and remaining confined to the prostate initially. It is common in men aged 50–64 years and over 65, though it can occur in men younger than 50. Symptoms include blood in the semen, frequent urge to urinate, and painful urination and ejaculation, which typically do not appear until the prostate enlarges enough to affect the urinary tract.

Metastatic castration-resistant prostate cancer represents the more prevalent subtype of advanced prostate cancer in the 7MM. Diagnosis involves PSA level analysis, digital rectal exams, biopsy, genetic testing, imaging tests such as ultrasound or MRI, and occasionally bone scans to check for metastasis. Treatment options span surgery, radiation therapy, hormone therapy, immunotherapy, and chemotherapy, with chemotherapeutic agents including docetaxel, cabazitaxel, mitoxantrone, and estramustine used once hormone therapy proves ineffective.

Get a Free Sample for the mCRPC Market Report: https://www.delveinsight.com/report-store/metastatic-castration-resistant-prostate-cancer-mcrpc-market 

Key Trends in the mCRPC Therapeutics Market:

• PARP Inhibitor Consolidation: Four PARP inhibitors — olaparib, niraparib, rucaparib, and talazoparib — are now FDA-approved for men with mCRPC harboring select HRR pathway alterations, improving progression-free and overall survival.
• Radioligand Therapy Expansion: Following PLUVICTO's approval, a wave of radioligand candidates, including 177Lu-PSMA-I&T, 177Lu-PNT2002, 177Lu-DOTA-rosopatamab, and actinium-225-based FPI-2265, are advancing through late-stage development to challenge or complement PLUVICTO in progressing mCRPC.
• Androgen Receptor Pathway Dominance: Four approved androgen receptor pathway inhibitors — apalutamide, enzalutamide, darolutamide, and abiraterone acetate — remain the mainstay of mCRPC treatment, with XTANDI and abiraterone acetate most heavily prescribed in first- and second-line real-world settings.
• Emerging ADC and Bispecific Interest: Antibody-drug conjugates targeting B7-H3, such as MGC018, and bispecific antibodies like vudalimab and zenocutuzumab, are generating early investigator interest in a disease historically unresponsive to checkpoint inhibitors.
• Line-of-Therapy Diversification: New candidates are being developed across first- (Opevesostat, Masofaniten, TAVT-45), second- (CABOMETYX), and third-line-and-beyond settings (177Lu-PNT2002, FPI-2265, ARV-766), broadening the competitive landscape at every treatment stage.
• Market Access Innovation: Payment models and copay assistance programs, such as those supporting TALZENNA, are being adopted by payers to reduce the healthcare burden of high-cost mCRPC therapies.

Metastatic Castration-Resistant Prostate Cancer Epidemiology

The report on mCRPC epidemiology provides a comprehensive analysis of the disease's prevalence, incidence, and patient demographics across the 7MM, covering the study period 2022–2036. It captures total prevalent and diagnosed cases of prostate cancer, age-specific and clinical-stage-specific distributions, and total prevalent and treated cases of mCRPC specifically.

mCRPC Epidemiology Segmentation:

• Total Prevalent Cases of Prostate Cancer
• Total Diagnosed Cases of Prostate Cancer
• Age-specific Cases of Prostate Cancer
• Total Diagnosed Cases of Prostate Cancer by Clinical Stages
• Total Cases of mCRPC
• Total Treated Cases of mCRPC

Download the report to understand which factors are driving mCRPC epidemiology trends @ Metastatic Castration-Resistant Prostate Cancer Epidemiology Forecast

Recent Developments in the mCRPC Treatment Landscape:

• In June 2026: Convergent Therapeutics Inc. announced interim results from Part 3 of its Phase 2 CONVERGE-01 trial evaluating Ac-225 rosopatamab tetraxetan (CONV01-α) in mCRPC patients previously treated with Lu-177-PSMA radioligand therapy.
• In May 2026: Johnson & Johnson reported final Phase 3 PROTEUS trial results showing that ERLEADA (apalutamide) combined with androgen deprivation therapy, administered for six months before and after prostate cancer surgery, significantly improved short- and long-term clinical outcomes versus placebo plus ADT in high-risk localized or locally advanced prostate cancer.
• In May 2026: Bayer reported that the Phase II ARACOG (AFT-47) head-to-head study met its primary endpoint, with NUBEQA (darolutamide) showing significantly less cognitive decline than enzalutamide by week 24 (median maximal change in cognitive domain of −15.8% vs. −36.1%, p=0.009) in CRPC and mCSPC patients, in a trial conducted by the Alliance Foundation Trials.
• In February 2026: K36 Therapeutics announced that data from its Phase I clinical trial of KTX-2001 would be presented as a Trial in Progress poster at the ASCO Genitourinary Cancers Symposium in San Francisco.
• In February 2026: Vir Biotechnology presented updated Phase 1 data for VIR-5500, a PSMA-targeting PRO-XTEN dual-masked T-cell engager, in heavily pretreated patients with advanced mCRPC.

mCRPC Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of potential drugs recently launched or expected to launch in the mCRPC market during the study period, covering market uptake by drug, patient uptake by therapy, and sales of each drug. A medium-fast uptake is expected for POINT Biopharma's PSMA [Lu-177]-PNT2002, though the drug faces increased pressure following PLUVICTO's approval and must demonstrate superior clinical performance and cost-effectiveness to gain significant market share.

The report also covers pipeline development activities, including collaborations, acquisitions, mergers, licensing, patent details, and other developments for emerging mCRPC therapies.

mCRPC Therapies and Key Companies

• Mevrometostat (PF-06821497) + enzalutamide: Pfizer
• TAVT-45 (abiraterone acetate): Tavanta Therapeutics
• 177Lu-PSMA-I&T: Curium
• Opeesostat (MK-5684; ODM-208): Merck and Orion
• ERLEADA (apalutamide): Janssen Pharmaceutical
• CABOMETYX (cabozantinib): Exelixis, Ipsen Pharma, and Takeda
• TRUQAP (capivasertib): AstraZeneca
• Masitinib: AB Science
• 177Lu-PNT2002: Lantheus and Eli Lilly/POINT Biopharma
• 177Lu-DOTA-rosopatamab (TLX591): Telix Pharmaceuticals
• Fuzuloparib: Jiangsu Hengrui Pharmaceuticals
• KPG-121: Kangpu Biopharmaceuticals
• FPI-2265: AstraZeneca/Fusion Pharma
• Zenocutuzumab: Merus
• BMS-986218: Bristol-Myers Squibb
• SX-682: Syntrix Pharmaceuticals
• PT-112: Promontory Therapeutics
• Vudalimab (XmAb-20717): Xencor
• Vobramitamab Duocarmazine (MGC018): MacroGenics

To know more about mCRPC companies working in the treatment market, visit @ Metastatic Castration-Resistant Prostate Cancer Clinical Trials and Therapeutic Assessment

mCRPC Market Drivers

• Rising prevalence of mCRPC driven by an aging population, increased prostate cancer diagnosis, and growing awareness of advanced disease management
• Diverse and expanding therapeutic landscape spanning androgen receptor inhibitors, PARP inhibitors, CYP17 inhibitors, microtubule inhibitors, and radioligand therapies
• Strong real-world adoption of XTANDI and abiraterone acetate in first- and second-line settings, reinforcing market penetration
• Label expansions of approved therapies alongside the launch of innovative emerging therapies across multiple treatment lines
• Notable revenue generation from radioligand therapies such as PLUVICTO, encouraging continued investment in PSMA-targeted approaches
• Robust pipeline activity from companies including Merck, Novartis, AstraZeneca, Eli Lilly/POINT Biopharma, Arvinas, and ESSA Pharma across first-, second-, and third-line settings

mCRPC Market Barriers

• Persistently high barriers to testing for targetable mutations despite multiple expert guidelines recommending it prior to therapy initiation
• Country-specific accessibility issues surrounding expensive, recently approved mCRPC therapies
• Pricing variations across geographies for approved and off-label mCRPC therapies affecting uniform market access
• Competitive pressure among emerging radioligand and targeted therapies to demonstrate superiority over established options like PLUVICTO
• mCRPC remaining a lethal diagnosis despite the treatment armamentarium, underscoring the continued need for more effective therapeutic approaches

Scope of the mCRPC Market Report

• Study Period: 2022–2036
• Forecast Period: 2026–2036
• Coverage: 7MM — United States, EU4 (Germany, France, Italy, and Spain), United Kingdom, and Japan
• Key mCRPC Companies: Curium, Bristol-Myers Squibb, Merck and Orion, Pfizer, Merus, Zenith Epigenetics, MacroGenics, Laekna Therapeutics, Ipsen, AstraZeneca, Telix International, ESSA Pharma, Arvinas and Novartis, Lantheus, Eli Lilly/POINT Biopharma, Xencor, Promontory Therapeutics, and others
• mCRPC Therapeutic Assessment: Current marketed and emerging mCRPC therapies
• mCRPC Market Dynamics: Market drivers and barriers
• Competitive Intelligence Analysis: SWOT analysis, conjoint analysis, and expert insights/KOL views
• mCRPC Unmet Needs, KOL's Views, Market Access, and Reimbursement

Discover more about therapies set to grab major mCRPC market share @ Metastatic Castration-Resistant Prostate Cancer Treatment Market

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefit market analysis to accelerate business growth and overcome challenges with a practical approach.